Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Juglone eliminates MDSCs accumulation and enhances antitumor immunity.

Wang H, Zou C, Zhao W, Yu Y, Cui Y, Zhang H, E F, Qiu Z, Zou C, Gao X.

Int Immunopharmacol. 2019 Aug;73:118-127. doi: 10.1016/j.intimp.2019.04.058. Epub 2019 May 11.

PMID:
31085459
2.

IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.

Lim HX, Choi S, Cho D, Kim TS.

Immunol Cell Biol. 2017 Jan;95(1):99-107. doi: 10.1038/icb.2016.72. Epub 2016 Aug 10.

PMID:
27507556
3.

Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.

Sumida K, Wakita D, Narita Y, Masuko K, Terada S, Watanabe K, Satoh T, Kitamura H, Nishimura T.

Eur J Immunol. 2012 Aug;42(8):2060-72. doi: 10.1002/eji.201142335.

4.

Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells.

Shime H, Maruyama A, Yoshida S, Takeda Y, Matsumoto M, Seya T.

Oncoimmunology. 2017 Sep 21;7(1):e1373231. doi: 10.1080/2162402X.2017.1373231. eCollection 2017.

5.

Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.

Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, Luyckx A, De Baetselier P, Van Ginderachter JA.

Eur J Immunol. 2013 Nov;43(11):2930-42. doi: 10.1002/eji.201343349. Epub 2013 Aug 25.

6.

IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells.

Lim HX, Hong HJ, Cho D, Kim TS.

J Immunol. 2014 Dec 1;193(11):5453-60. doi: 10.4049/jimmunol.1401282. Epub 2014 Oct 31.

7.

Downregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors.

Shen J, Chen X, Wang Z, Zhang G, Chen W.

Oncol Lett. 2014 Aug;8(2):775-780. Epub 2014 May 26.

8.

Suppression of T cells by myeloid-derived suppressor cells in cancer.

Chen J, Ye Y, Liu P, Yu W, Wei F, Li H, Yu J.

Hum Immunol. 2017 Feb;78(2):113-119. doi: 10.1016/j.humimm.2016.12.001. Epub 2016 Dec 7. Review.

PMID:
27939507
9.

Modulation of myeloid derived suppressor cells (MDSCs) functions: a new strategy towards hydrogen sulfide anti-cancer effects.

De Cicco P, Ercolano G, Rubino V, Terrazzano G, Ruggiero G, Cirino G, Ianaro A.

Br J Pharmacol. 2019 Aug 7. doi: 10.1111/bph.14824. [Epub ahead of print]

PMID:
31392723
10.
11.

Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer.

Liu D, You M, Xu Y, Li F, Zhang D, Li X, Hou Y.

Int Immunopharmacol. 2016 Oct;39:265-272. doi: 10.1016/j.intimp.2016.07.035. Epub 2016 Aug 4.

PMID:
27497194
12.
13.

The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury.

Zhang C, Wang S, Li J, Zhang W, Zheng L, Yang C, Zhu T, Rong R.

Cell Death Dis. 2017 Mar 23;8(3):e2695. doi: 10.1038/cddis.2017.86.

14.

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.

Grauers Wiktorin H, Nilsson MS, Kiffin R, Sander FE, Lenox B, Rydström A, Hellstrand K, Martner A.

Cancer Immunol Immunother. 2019 Feb;68(2):163-174. doi: 10.1007/s00262-018-2253-6. Epub 2018 Oct 12.

15.

Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer.

Capietto AH, Kim S, Sanford DE, Linehan DC, Hikida M, Kumosaki T, Novack DV, Faccio R.

J Exp Med. 2013 Oct 21;210(11):2257-71. doi: 10.1084/jem.20130281. Epub 2013 Oct 14.

16.

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.

17.

Oncolytic Reovirus Inhibits Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in a TLR3-Dependent Manner.

Katayama Y, Tachibana M, Kurisu N, Oya Y, Terasawa Y, Goda H, Kobiyama K, Ishii KJ, Akira S, Mizuguchi H, Sakurai F.

J Immunol. 2018 Apr 15;200(8):2987-2999. doi: 10.4049/jimmunol.1700435. Epub 2018 Mar 19.

18.

Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer.

Pogoda K, Pyszniak M, Rybojad P, Tabarkiewicz J.

Oncol Lett. 2016 Dec;12(6):4785-4794. doi: 10.3892/ol.2016.5273. Epub 2016 Oct 18.

19.

MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.

Wang J, Yu F, Jia X, Iwanowycz S, Wang Y, Huang S, Ai W, Fan D.

Int J Cancer. 2015 Mar 15;136(6):E602-13. doi: 10.1002/ijc.29151. Epub 2014 Aug 30.

20.

Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.

Li G, Wu K, Tao K, Lu X, Ma J, Mao Z, Li H, Shi L, Li J, Niu Y, Xiang F, Wang G.

Mol Med Rep. 2015 Jul;12(1):760-8. doi: 10.3892/mmr.2015.3374. Epub 2015 Feb 18.

PMID:
25695487

Supplemental Content

Support Center